- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
Patent holdings for IPC class A61K 31/439
Total number of patents in this class: 2475
10-year publication summary
|
180
|
191
|
200
|
209
|
180
|
186
|
168
|
144
|
192
|
119
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Wockhardt Limited | 195 |
48 |
| Genzyme Corporation | 1367 |
46 |
| Lenz Therapeutics Operations, Inc. | 48 |
42 |
| Merck Sharp & Dohme LLC | 3732 |
30 |
| Chiesi Farmaceutici S.p.A. | 962 |
29 |
| Novartis AG | 10309 |
28 |
| AstraZeneca AB | 2821 |
26 |
| Boehringer Ingelheim International GmbH | 4500 |
25 |
| Vertex Pharmaceuticals Incorporated | 1587 |
24 |
| Meiji Seika Pharma Co., Ltd. | 256 |
24 |
| Bristol-myers Squibb Company | 4721 |
22 |
| Centre National de La Recherche Scientifique | 10976 |
17 |
| The Scripps Research Institute | 1342 |
17 |
| Theravance Biopharma R&D IP, LLC | 409 |
17 |
| Glaxo Group Limited | 4380 |
15 |
| Oyster Point Pharma, Inc. | 79 |
14 |
| Achieve Life Sciences, Inc. | 44 |
14 |
| Skyhawk Therapeutics, Inc. | 147 |
14 |
| The Regents of the University of California | 20669 |
13 |
| Astellas Pharma Inc. | 1042 |
13 |
| Other owners | 1997 |